Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)
emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)
jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential

Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)
office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain

25. November 2019 | 05:54 CET

MPH Health Care investment HAEMATO with growth in Q3 - shares before turnaround?

  • Medical

HAEMATO AG, a provider of special pharmaceuticals and a subsidiary of MPH Health Care, which is also listed on the stock exchange, returned to growth in the third quarter of 2019. The company is also continuing to optimize its business processes and approve new products in order to broaden its portfolio. This means that the stocks could also face a turnaround. Analysts also see significant price potential.

time to read: 1 minutes by Mario Hose

 

Solid healthcare market environment

After HAEMATO was able to shine with solid growth and high dividends in the past years, the streamlining of the portfolio with low-margin products and the expiration of patents for some high-revenue original preparations led to a decline in sales in 2018 and especially in the first half of 2019. This phase now seems to have been overcome. The fundamentally solid outlook for the healthcare market has not changed.

Specialization in drugs

As one of the leading suppliers of special pharmaceuticals, the HAEMATO Group benefits from competition in the first healthcare market. The specialisation in drugs for the treatment of chronic diseases and for individual therapies is expected to remain positive in the future due to demographic developments.

Analysts see clear potential

The analysts of First Berlin and GBC Research see clear price potential. Both recommend buying the HAEMATO stocks. The price targets are EUR 4.80 (First Berlin) and EUR 6 (GBC). GBC sees the conclusion of the framework agreement between the GKV (Central Association of Health Insurance Funds) and the German Pharmacy Association as a good basis for continued high demand for HAEMATO products.

In addition, new sources of revenue are to be tapped. In addition to the parallel imports business segment, the area of pharmaceutical, medical and medical technology products for aesthetic treatments and cosmetics is to be addressed in future. The first hyaluronic acid-based products, which are distributed via the pharmacy network, were introduced in Germany in 2018. The listed investments of MPH also include M1 Kliniken AG and CR Real Estate AG.

Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.

Related comments:

Evotec, Medigene, Memphasys - the right investment timing

05. May 2020 | 08:33 CET

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

Read

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

24. April 2020 | 07:36 CET

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

Read

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read